← Back to Search

Topical Gel

LEV102 Topical Gel, 2.0% for Droopy Eyelid

Phase 1 & 2
Waitlist Available
Research Sponsored by Levation Pharma, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must have complaints of aesthetically unacceptable upper eyelid position for both eyes making them desirous for elevation, or have complaints of superior visual field defects in both eyes that impact activities of daily living
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2-5
Awards & highlights

Study Summary

This trial tests a new treatment for droopy eyelids in adults, comparing it to a placebo.

Eligible Conditions
  • Droopy Eyelid

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You want to lift your upper eyelids because you don't like how they look or they are affecting your ability to see properly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 2-5
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 2-5 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
Secondary outcome measures
Upper eyelid height

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LEV102 Topical Gel, 2.0%Experimental Treatment1 Intervention
Group II: LEV102 Topical Gel, 1.0%Experimental Treatment1 Intervention
Group III: VehiclePlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LEV102 2.0%
2023
Completed Phase 2
~40
LEV102 1.0%
2023
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Levation Pharma, Ltd.Lead Sponsor
Houman D Hemmati, MD PhDStudy ChairLevation Pharma, Ltd.

Media Library

LEV102 (Topical Gel) Clinical Trial Eligibility Overview. Trial Name: NCT05715346 — Phase 1 & 2
Droopy Eyelid Research Study Groups: LEV102 Topical Gel, 2.0%, LEV102 Topical Gel, 1.0%, Vehicle
Droopy Eyelid Clinical Trial 2023: LEV102 Highlights & Side Effects. Trial Name: NCT05715346 — Phase 1 & 2
LEV102 (Topical Gel) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05715346 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size of this medical research project?

"Affirmative, the information listed on clinicaltrials.gov indicates that this experiment is actively recruiting participants. It was initially posted on February 28th 2023 and its most recent revision occurred on March 5th of the same year. The researchers need to source 30 patients from 3 distinct medical facilities."

Answered by AI

Is the study currently enrolling participants?

"Affirmative, data found on clinicaltrials.gov suggests that this research is actively recruiting patients. Initially published on February 28th of 2023, the trial's most recent update was made in March 5th and it seeks 30 participants from 3 different sites."

Answered by AI

Can individuals aged 75 and under gain access to this clinical experiment?

"The age range for applicants in this medical study is 25 to 99. For those outside the eligibilty criteria, there are 2 clinical trials intended for minors and 7 associated with elderly patients."

Answered by AI

Is it possible to volunteer for this research study?

"This clinical trial will enrol 30 individuals with ptosis aged between 25 and 99. Eligibility necessitates: being male or female, having complaints of aesthetically displeasing upper eyelids that need elevation, visual field defects impacting daily activities in both eyes, a minimum MRD1 measurement ≤2 mm in one eye (no visible central pupillary light reflex defaults to 0) and current corrected VA of +0.3 LogMAR or better as assessed by ETDRS for the same eye; furthermore all women of childbearing potential must use an approved form of contraception from signing consent until after the last study visit; finally participants must be able"

Answered by AI
~19 spots leftby Mar 2025